Evidence map›Paper›PMID 41279410›Full record

ArticlebioRxiv : the preprint server for biology2025

IGF2BP3 remodels the microRNA targeting landscape in MLL-AF4 leukemia.

Lyna E S Kabbani, Shruti Kapoor, Gunjan Sharma, Martin Gutierrez, Zachary T Neeb, Amit Kumar Jaiswal, Alexander J Ritter, Sol Katzman, Jordyn Feldman, Dinesh S Rao and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lyna E S KabbaniDepartment of Molecular, Cell and Developmental Biology and Center for Molecular Biology of RNA, University of California Santa Cruz, Santa Cruz, CA.
Shruti KapoorDepartment of Molecular, Cell and Developmental Biology and Center for Molecular Biology of RNA, University of California Santa Cruz, Santa Cruz, CA.
Gunjan SharmaDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0003-3110-9239
Martin GutierrezDepartment of Molecular, Cell and Developmental Biology and Center for Molecular Biology of RNA, University of California Santa Cruz, Santa Cruz, CA.
Zachary T NeebDepartment of Molecular, Cell and Developmental Biology and Center for Molecular Biology of RNA, University of California Santa Cruz, Santa Cruz, CA.ORCID 0000-0001-8930-3574
Amit Kumar JaiswalDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA.
Alexander J RitterDepartment of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA 95064, USA.
Sol KatzmanCenter for Biomolecular Science and Engineering, University of California Santa Cruz, Santa Cruz, CA.
Jordyn FeldmanDepartment of Molecular, Cell and Developmental Biology and Center for Molecular Biology of RNA, University of California Santa Cruz, Santa Cruz, CA.
Dinesh S RaoDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA.
Jeremy R SanfordDepartment of Molecular, Cell and Developmental Biology and Center for Molecular Biology of RNA, University of California Santa Cruz, Santa Cruz, CA.ORCID 0000-0002-1131-1627

Funding

A postdoctoral training program for impactful careers in stem cell biologyT32HD108079 · NICHD · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI Bin Chen, CAMILLA FORSBERG · 2022 to 2026
$1.1M
NICHD NIH HHS T32 HD108079
6 · The paper itself

Abstract

Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3/I3) is a multi-domain RNA-binding protein required for MLL-AF4-driven leukemogenesis, but its mechanism of action remains enigmatic. We hypothesized from our previous work that I3 amplifies oncogenic gene expression by modulating RNA induced silencing complex (RISC) mRNA interactions. To test this, we performed miR-eCLIP of AGO2, the catalytic RISC subunit, in I3 knock-out (I3KO) as well as control B-cell acute lymphoblastic cell lines (B-ALL) and identified I3-dependent AGO2 binding sites on 111 3'UTRs. Analyzing chimeric miRNA-mRNA reads, we observed differential miRNA occupancy in the I3KO compared to control, including increased targeting by miR-181a, a regulator of leukocyte differentiation. Notably, miR-181a overexpression phenocopied I3 loss, implicating I3 in restricting miR-181a-mediated repression. Biochemical assays confirmed direct competition between I3 and AGO2-miRNA complexes for 3'-UTR binding. Taken together, our results provide a model for how I3 promotes leukemogenesis by antagonizing RISC-mediated repression of oncogenic mRNAs.

Identifiers

PMID41279410
PMCPMC12632767

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.